The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2022 | CD38-targeting triplets for myeloma
Michele Cavo, MD, PhD, Bologna University School of Medicine, Bologna, Italy, highlights the importance of CD38-targeting triplets for the treatment of multiple myeloma, drawing focus on the promise that these combination therapies provide for patients with relapsed/refractory (R/R) disease. Prof. Cavo also mentions the improved progression-free survival (PFS) observed in several triplet combinations such as a monoclonal antibody plus pomalidomide and dexamethasone. This interview took place at the 8th World Congress on Controversies in Multiple Myeloma (COMy) 2022, held in Paris, France.
